Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma

This publication is a narrative review focusing on preclinical and early clinical strategies for B-cell non-Hodgkin's lymphoma. It examines the combined treatment of small molecule targeted drugs, including BTK inhibitors and Bcl-2 inhibitors, alongside CAR-T cell therapy in patients progressing into relapsed or refractory disease. The review outlines the rationale for this combination approach without reporting specific sample sizes or settings, acknowledging the early nature of the evidence base.

The authors synthesize arguments regarding how these targeted drugs may improve the tumor microenvironment and enhance the function of CAR-T cells. Proposed mechanisms include improving the sensitivity of tumor cells to CAR-T therapy, inhibiting exhaustion, and potentially reducing toxicity. These qualitative conclusions suggest a theoretical benefit in overcoming resistance mechanisms observed with single agents, though the authors note limited single-drug efficacy as a barrier.

The authors acknowledge significant limitations, including limited single-drug efficacy, drug-resistant recurrence, and toxic reactions. Safety data regarding adverse events, serious adverse events, and discontinuations are not reported within this review. Consequently, practice relevance is currently limited, as further in-depth research is needed to promote its clinical transformation and application. Clinicians should interpret these findings cautiously given the preclinical and early clinical phase status and the explicit note to not overstate efficacy evidence.